| | Financial incentive programs for electronic health records
| | Physicians report having a great interest in obtaining federal funds for adopting electronic health record technology, but two barriers to such adoption are lack of information about how to receive federal incentive funds and concerns about the initial cost of adopting EHRs. | |  |
|
|
| Clinicians concerned about safety, efficacy of biosimilar drugs
| | | Biosimilars are designed to mimic biologic agents, but they are not precise duplicates of these drugs. Biosimilars may prove useful for treating skin conditions such as psoriasis, but clinicians are waiting for guidance on the drugs from the Food and Drug Administration, which was still pending at press time. |
| | Budget crunch, political battles shape 2012 policy agenda
| | | Election-year politics will color a range of legislative and policy developments affecting drug development, production, and reimbursement in the coming year, as efforts to reduce government spending on healthcare prompts all parties to search for opportunities to do more with less. Looming over the political landscape is the upcoming Supreme Court decision on the constitutionality of the Obama health reform legislation. |
| | | FDA promotes innovation, access to medicines while modernizing operations
| | | FDA is under pressure to encourage medical product development, monitor an increasingly global supply chain, and accomplish everything with ever-tighter resources. In the last few years, Congress added tobacco oversight to FDA's plate and expanded oversight of food safety, on top of mandates speeding new therapies to market while ensuring they are safe and risk-free. |
| |
| 
Practice Tools
